RealTime Dynamix™: Rheumatoid Arthritis Q2
RealTime Dynamix: Rheumatoid Arthritis Q2 is the second instalment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. The Q2 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of […]
Despite An Increase in Psoriatic Arthritis Patients Initiated on Cosentyx Over the Past Three Months, the User Base for Novartis’ IL-17 Inhibitor Has Remained Stable
Download Report Overview ZUG, Switzerland, Nov. 2, 2016 /PRNewswire/ — A recent study of nearly 100 surveyed US rheumatologists reveals that after approximately nine months on the market, not only are current users of Novartis’ Cosentyx reporting increased PsA initiations, but the brand has also made significant gains in biologic patient share. Despite increased overall […]
Direct to Consumer Campaigns for Pfizer’s Xeljanz, Abbvie’s Humira, and Amgen’s Enbrel the Most Influential with RA Patients
Despite the reported influence of DTC campaigns on RA patients, US rheumatologists doubt the effectiveness and appropriateness of brand advertising in RA, according to Spherix Global Insights Download Report Overview October 25, 2016 – Cambridge, Massachusetts. Survey responses of nearly 100 US rheumatologists reveal that RA patients are significantly more influenced by the DTC campaigns […]
Market Access Obstructs Newer Biologic and JAK Adoption in Rheumatoid Arthritis
Download Report Overview Despite frequent involvement with payers for the approval of biologics/JAKs in RA, rheumatologists report that their use is heavily impacted by the negative reimbursement and access environment, according to a recent report from Spherix Global Insights. August 19, 2016 – Cambridge, Massachusetts. While the majority of surveyed rheumatologists (n=100) report that access […]
User Base for Novartis’ Cosentyx in Psoriatic Arthritis Significantly Expands as Rheumatologists Report High Satisfaction
Download Report Overview At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase from the 24% who reported use at one month post-launch, according to a recent report from Spherix Global Insights. August 11, 2016 – Cambridge, Massachusetts. US rheumatologists are increasingly adopting Novartis’ IL-17 inhibitor, Cosentyx, into […]
Pfizer’s Xeljanz Benefits from Biologic Switching in Rheumatoid Arthritis, According to Spherix Global Insights
Download Report Overview Analysis of RA patients switched from one biologic/JAK to another brand in the past three months indicate that Xeljanz has the greatest net gains when switching occurs. May 12, 2016, Zug, Switzerland – Spherix Global Insights reveals that Xeljanz is carving a niche as a popular switch-to-agent in second and later lines […]
Psoriatic Arthritis Patients Play A Substantial Role in Biologic Switching Decisions. Cimzia and Otezla Benefit Most From Patient Involvement, According to Spherix Global Insights
Download Report Overview A recent survey conducted by Spherix Global Insights reveals that psoriatic arthritis (PsA) patients play an important role in the decision to switch to – and from – biologics/Otezla. Specifically, the RealWorld Dynamix™: Biologic & Otezla Switching in Psoriatic Arthritisreport finds that in two-thirds of patients who have recently switched brands, the patient […]
Pfizer’s Newly Approved Once-Daily Xeljanz XR Is Unlikely To Expand Overall Brand Use According To The Latest Rheumatology Report
Download Report Overview A recent survey conducted by Spherix Global Insights with U.S. rheumatologists (n=96) in February indicates that despite increased dosing options for Pfizer’s Xeljanz, most physicians do not anticipate their overall use of the JAK inhibitor to change. Though 28% foresee that the QD dosing option may increase their use of Xeljanz, 17% […]
Rheumatologists Report Widespread Adoption and Anticipated Gains for Celgene’s Otezla in Psoriatic Arthritis
TNF share expected to erode as Otezla sees greater adoption, according to Spherix Global Insights, GmbH September 8, 2015 – Zug, Switzerland – Feedback gathered from 101 US rheumatologists during late July and early August reveals a major shift in PsA treatment focused on the uptake and expanded use of Otezla. According to the latest […]
Rheumatologists Plan to Increase their Use of Pfizer’s Xeljanz, Janssen’s Simponi and Roche’s Actemra in the Next Month
Over 40% of current Xeljanz users expect to increase use, with many rheumatologists initiating the agent prior to biologics, according to Spherix Global Insights, GmbH September 1, 2015 – Zug, Switzerland – Feedback gathered from 101 rheumatologists in August reveals that while anti-TNF inhibitors remain entrenched in most practices, use of Xeljanz, Actemra and Simponi […]
